Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune checkpoint inhibitors (ICI) in advanced solid tumors
Published in Journal of Clinical Oncology, 2022
Recommended citation: Adib, E., Nassar, A., El Zarif, T., Kale, N., Rakaee, M., Mouhieddine, T. H., Abou Alaiwi, S., Freeman, D., Labban, M., Akl, E., Haddad, R. I., Hodi, F. S., Sonpavde, G. P., Giannakis, M., Braun, D. A., Gusev, A., Choueiri, T. K., Overstreet, E., Stone, E., & Kwiatkowski, D. J. (2022). "Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors." Journal of Clinical Oncology, 40(16_suppl), 2622–2622. https://doi.org/10.1200/jco.2022.40.16_suppl.2622
This conference paper was presented at ASCO Annual Meeting I. We investigate the impact of CDKN2A and MTAP genomic alterations on the response to immune checkpoint inhibitors in cancer patients and finds that the co-occurrence of MTAP/CDKN2A alterations is associated with poorer outcomes, particularly in urothelial carcinoma and melanoma, accompanied by lower tumor-infiltrating lymphocyte density in melanoma samples with both alterations.